162 related articles for article (PubMed ID: 32351985)
1. Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer.
Zhou J; Jiang W; Huang W; Ye M; Zhu X
Biomed Res Int; 2020; 2020():2170606. PubMed ID: 32351985
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of
Chetry M; Li S; Liu H; Hu X; Zhu X
Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29472315
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer.
Zhou J; Xu Y; Chen X; Chen F; Zhang J; Zhu X
J Cancer; 2021; 12(23):7147-7157. PubMed ID: 34729116
[No Abstract] [Full Text] [Related]
4. The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S; Hu X; Ye M; Zhu X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
[No Abstract] [Full Text] [Related]
5. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.
Do TV; Kubba LA; Du H; Sturgis CD; Woodruff TK
Mol Cancer Res; 2008 May; 6(5):695-705. PubMed ID: 18505915
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the lysyl oxidase family in ovarian cancer.
Ye M; Zhou J; Gao Y; Pan S; Zhu X
J Clin Lab Anal; 2020 Dec; 34(12):e23538. PubMed ID: 33058284
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Bristow RE; Baldwin RL; Yamada SD; Korc M; Karlan BY
Cancer; 1999 Feb; 85(3):658-68. PubMed ID: 10091739
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
10. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.
Yan Z; Tian X; Wang R; Cheng X; Mi J; Xiong L; Wang Y; Deng J; Jia M
Int J Gynecol Cancer; 2017 Sep; 27(7):1343-1349. PubMed ID: 30814239
[TBL] [Abstract][Full Text] [Related]
11. Expression of RRBP1 in epithelial ovarian cancer and its clinical significance.
Ma J; Ren S; Ding J; Liu S; Zhu J; Ma R; Meng F
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31285390
[TBL] [Abstract][Full Text] [Related]
12. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Inan S; Vatansever S; Celik-Ozenci C; Sanci M; Dicle N; Demir R
Histol Histopathol; 2006 Oct; 21(10):1055-64. PubMed ID: 16835828
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma.
Bellone G; Carbone A; Tibaudi D; Mauri F; Ferrero I; Smirne C; Suman F; Rivetti C; Migliaretti G; Camandona M; Palestro G; Emanuelli G; Rodeck U
Eur J Cancer; 2001 Jan; 37(2):224-33. PubMed ID: 11166150
[TBL] [Abstract][Full Text] [Related]
14. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast.
Chakravarthy D; Green AR; Green VL; Kerin MJ; Speirs V
Int J Oncol; 1999 Jul; 15(1):187-94. PubMed ID: 10375614
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
16. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer.
Dong Y; Li J; Han F; Chen H; Zhao X; Qin Q; Shi R; Liu J
Oncol Rep; 2015 Aug; 34(2):936-42. PubMed ID: 26063585
[TBL] [Abstract][Full Text] [Related]
17. The prognostic values of signal transducers activators of transcription family in ovarian cancer.
Li S; Sheng B; Zhao M; Shen Q; Zhu H; Zhu X
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28536310
[TBL] [Abstract][Full Text] [Related]
18. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
El-Etreby NM; Ghazy AA; Rashad R
J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer.
Chetry M; Bhandari A; Lin Y
J Cancer; 2022; 13(5):1695-1705. PubMed ID: 35371325
[No Abstract] [Full Text] [Related]
[Next] [New Search]
